Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792353 | 0.94 | MMP3 (0.35) | MMP3BCL2L1FNTAFNTB | |
| SCHEMBL29561685 | 0.93 | MMP3 (0.33) | MMP3BCL2L1FNTAFNTBLMNA | |
| SCHEMBL4852324 | 0.85 | MMP3 (0.42) | MMP3BCL2L1FNTAFNTBLMNA | |
| SCHEMBL155778 | 0.84 | MMP3 (0.43) | MMP3BCL2L1FNTAFNTBLMNA | |
| Hydrochloric Acid SCHEMBL3038821 | 0.83 | MMP3 (0.41) | MMP3BCL2L1FNTAFNTBLMNA | |
| SCHEMBL2233590 | 0.82 | SHBG (0.32) | — | |
| SCHEMBL30931353 | 0.82 | LMNA (0.38) | MMP3BCL2L1FNTAFNTBLMNA | |
| SCHEMBL29696673 | 0.82 | LMNA (0.38) | MMP3BCL2L1FNTAFNTBLMNA | |
| SCHEMBL30782244 | 0.82 | LMNA (0.38) | MMP3BCL2L1FNTAFNTBLMNA | |
| SCHEMBL30243179 | 0.81 | GAA (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634262-A1 | ONE-COMPONENT CATIONIC POLYMERIZABLE COMPOSITION | Huntsman Advanced Materials (Switzerland) GmbH (CH) | 2025-10-22 | — | — | EP | disclosed |
| CN-113924341-B | Sealing sheet | 琳得科株式会社 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024126186-A1 | ONE-COMPONENT CATIONIC POLYMERIZABLE COMPOSITION | HUNTSMAN ADVANCED MATERIALS LICENSING (SWITZERLAND) GMBH (CH) | 2024-06-20 | — | — | WO | disclosed |
| CN-113993958-B | Adhesive sheet for sealing device | 琳得科株式会社 | 2024-01-05 | — | — | CN | disclosed |
| CN-117222721-A | Curable adhesive composition, cured product, and method for producing cured product | 琳得科株式会社 | 2023-12-12 | — | — | CN | disclosed |
| US-20230151138-A1 | STEREOISOMER OF EPOXY COMPOUND, CURABLE COMPOSITION CONTAINING THE SAME, AND CURED PRODUCT OBTAINED BY CURING CURABLE COMPOSITION | ENEOS CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4130087-A1 | STEREOISOMER OF EPOXY COMPOUND, CURABLE COMPOSITION CONTAINING SAME, AND CURED OBJECT OBTAINED BY CURING CURABLE COMPOSITION | ENEOS Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-3345951-B1 | CURABLE COMPOSITION AND CURED ARTICLE USING SAME | SAN APRO LTD (JP) | 2020-07-01 | — | — | EP | disclosed |
| US-20180329297-A1 | CURABLE COMPOSITION AND CURED ARTICLE USING SAME | SAN-APRO LTD. (JP) | 2018-11-15 | — | — | US | disclosed |
| EP-3345951-A1 | CURABLE COMPOSITION AND CURED ARTICLE USING SAME | San-Apro Limited (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-20140212578-A1 | MAGNETIC SHEET COMPOSITION, MAGNETIC SHEET, AND METHOD FOR PRODUCING MAGNETIC SHEET | DEXERIALS CORPORATION (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8668792-B2 | Method for producing magnetic sheet | DEXERIALS CORPORATION (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8431654-B2 | Epoxy resin composition | SONY CHEMICAL & INFORMATION DEVICE CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120205025-A1 | METHOD FOR PRODUCING MAGNETIC SHEET | SONY CHEMICAL & INFORMATION DEVICE CORPORATION (JP) | 2012-08-16 | — | — | US | disclosed |
| EP-2161292-B1 | EPOXY RESIN COMPOSITION | SONY CHEM & INF DEVICE CORP (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20110192639-A1 | NOVEL SULFONIUM BORATE COMPLEX | SONY CHEMICAL & INFORMATION DEVICE CORPORATION (JP) | 2011-08-11 | — | — | US | disclosed |
| EP-2354123-A1 | NOVEL SULFONIUM BORATE COMPLEX | Sony Chemical & Information Device Corporation (JP) | 2011-08-10 | — | — | EP | disclosed |
| US-20110033732-A1 | MAGNETIC SHEET COMPOSITION, MAGNETIC SHEET, AND METHOD FOR PRODUCING MAGNETIC SHEET | SONY CHEMICAL & INFORMATION DEVICE CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20100193228-A1 | EPOXY RESIN COMPOSITION | SONY CHEMICAL & INFORMATION DEVICE CORPORATION (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2161292-A1 | EPOXY RESIN COMPOSITION | Sony Chemical & Information Device Corporation (JP) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151138-A1 | STEREOISOMER OF EPOXY COMPOUND, CURABLE COMPOSITION CONTAINING THE SAME, AND CURED PRODUCT OBTAINED BY CURING CURABLE COMPOSITION | PTGER1, SEM1, REV1 | MMP3 3774/4885BCL2L1 2876/4885FNTA 2483/4885 |
| US-20180329297-A1 | CURABLE COMPOSITION AND CURED ARTICLE USING SAME | INO80C, H1-0, H1-4 | MMP3 4118/4885BCL2L1 4114/4885FNTA 2364/4885 |
| US-20110192639-A1 | NOVEL SULFONIUM BORATE COMPLEX | EBPL, ITGB1, ITGA1 | MMP3 4153/4885BCL2L1 843/4885FNTA 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.